The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 23, 2024

Filed:

Jun. 22, 2018
Applicants:

Allovir, Inc., Waltham, MA (US);

Baylor College of Medicine, Houston, TX (US);

Wilson Wolf Manufacturing Corporation, New Brighton, MN (US);

Inventors:

Rainer Ludwig Knaus, London, GB;

Katy Rebecca Newton, London, GB;

Juan Vera, Houston, TX (US);

Ann Leen, Houston, TX (US);

Cliona Rooney, Bellaire, TX (US);

John R. Wilson, New Brighton, MN (US);

Assignees:

AlloVir, Inc., Waltham, MA (US);

Baylor College of Medicine, Houston, TX (US);

Wilson Wolf Manufacturing Corporation, New Brighton, MN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61K 39/12 (2006.01); A61K 39/235 (2006.01); A61K 39/245 (2006.01); C12M 1/04 (2006.01); C12N 5/0783 (2010.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 39/12 (2013.01); A61K 39/235 (2013.01); A61K 39/245 (2013.01); C12M 23/24 (2013.01); C12N 5/0636 (2013.01); C12N 7/00 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/55527 (2013.01); C12N 2501/2304 (2013.01); C12N 2501/2307 (2013.01); C12N 2506/11 (2013.01); C12N 2710/10034 (2013.01); C12N 2710/16134 (2013.01); C12N 2710/18034 (2013.01); Y02A 50/30 (2018.01);
Abstract

An in vitro expansion process for rapid expansion of antigen specific T cells, such as allogeneic antigen specific T cells comprising the steps culturing in a gas permeable vessel a population of PBMCs (such as allogeneic PBMCs) in the presence of antigen, for example a peptide or peptide mix relevant to a target antigen(s), in the presence of an exogenous cytokine characterized in that the expansion to provide the desired population of T cells is 14 days or less, for example 9, 10, 11 or 12 days, such as 10 days. The disclosure also extends to T cell populations generated by and obtained from the method and the use of same in therapy.


Find Patent Forward Citations

Loading…